Silence Therapeutics Plc Stock Price, News & Analysis

Silence Therapeutics has presented promising data from its APOLLO phase 1 study of SLN360, targeting elevated lipoprotein(a) (Lp(a)), a significant cardiovascular risk factor. Results showed that participants receiving 300 mg and 600 mg doses maintained median reductions in Lp(a) levels exceeding 80% over five months. Some maintained reductions of up to 50% of baseline at one year. No new safety concerns arose, suggesting SLN360's potential for infrequent dosing. The company plans to advance into a phase 2 study for patients with atherosclerosis in late 2022.

Silence Therapeutics plc, a leader in siRNA therapeutics, announced preliminary results from the GEMINI II phase 1 study of SLN124 targeting the TMPRSS6 gene in adults with non-transfusion dependent thalassemia. The study showed an encouraging safety profile with no serious adverse events or dose limiting toxicities. Pharmacokinetic and pharmacodynamic evaluations are ongoing, with results expected next year. SLN124 has received FDA Fast Track Designation for polycythemia vera, and a phase 1/2 trial is planned for later this year, showcasing its potential across various hematological conditions.

Silence Therapeutics plc (Nasdaq: SLN) announced that Giles Campion, MD, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 4 at 3:45 p.m. ET in New York. The event can be viewed live on the company's website. Silence Therapeutics focuses on developing innovative siRNA therapeutics targeting diseases with significant unmet medical needs, leveraging its mRNAi GOLD™ platform. Major products include SLN360 for cardiovascular risk and SLN124 for rare hematological diseases. Collaborations with AstraZeneca and others enhance their research efforts.

Silence Therapeutics, a leader in RNAi therapeutics, announced participation in two upcoming conferences in New York. The first is the Morgan Stanley Global Healthcare Conference, featuring a fireside chat on September 13, 2022, at 5:15 p.m. ET. The second is the H.C. Wainwright Global Investment Conference, with a fireside chat on September 14, 2022, at 4:00 p.m. ET. Investors can access webcasts of these chats on the company’s website. Silence focuses on developing siRNA therapeutics targeting diseases with significant unmet needs.

Silence Therapeutics has received Fast Track Designation from the FDA for SLN124, an siRNA targeting the TMPRSS6 gene, aimed at treating polycythemia vera (PV). This designation could accelerate the development and review process, enabling quicker patient access to treatments. SLN124 has shown proof of mechanism and tolerability in prior studies. The company also plans to initiate a phase 1/2 study this year and is evaluating SLN124 for other hematological diseases.

Silence Therapeutics plc (NASDAQ: SLN) announced pricing for an underwritten offering of 5,950,000 American Depositary Shares (ADSs) at $9.50 each, yielding approximately $56.5 million before expenses. The offering aims to fund clinical trials, including Phase 2 SLN360 for ASCVD and Phase 1/2 SLN124 for polycythemia vera. The offering is expected to close around August 16, 2022. Morgan Stanley and William Blair are joint book-running managers. Silence's focus is on RNA interference therapeutics targeting significant unmet medical needs.

Silence Therapeutics plc, a leader in siRNA therapeutics, announced its participation in the Jefferies Healthcare Conference on June 9, 2022, at 10:00 a.m. EDT / 2:00 p.m. GMT. The presentation will be accessible via a live webcast on the company’s website, with an archived replay available afterward. Silence is focused on RNA interference technology to develop treatments for diseases, with key products including SLN360 for cardiovascular risk and SLN124 for hematological disorders. The company collaborates with AstraZeneca and others.

Silence Therapeutics plc (NASDAQ: SLN) announced its participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The on-demand presentation will be available on May 23 at 7:00 AM ET via the Silence website. Silence specializes in RNA interference (RNAi) therapeutics targeting significant unmet medical needs. Key candidates include SLN360 for cardiovascular risk reduction and SLN124 for hematological diseases. The Company collaborates with AstraZeneca and others to advance its innovative therapies.

Silence Therapeutics plc (NASDAQ: SLN) reported its Q1 2022 financial results, highlighting progress in its development pipeline. Key achievements include positive SLN360 data presented at ACC and FDA orphan drug designation for SLN124. Financially, the company generated £5.7 million in revenue, up from £3.1 million in Q1 2021, while net loss decreased to £7.7 million from £8.4 million. As of March 31, 2022, cash and equivalents totaled £59.3 million. The company anticipates further milestones, including durability data for SLN360 and topline results for SLN124, both expected in Q3 2022.